BPC-157 is a synthetic 15-amino acid peptide derived from a protective protein in human gastric juice, studied primarily for accelerating tissue repair, reducing inflammation, and protecting the gut lining.
What it does
BPC-157 works through at least six overlapping molecular pathways, which is why researchers call it 'pleiotropic' — meaning it produces multiple effects through multiple routes simultaneously. Its dominant mechanism is angiogenesis: it upregulates VEGF (vascular endothelial growth factor) and its receptor VEGFR2, triggering the growth of new capillaries that carry nutrients to damaged tissue. It also activates eNOS (endothelial nitric oxide synthase), an enzyme that produces nitric oxide to widen blood vessels and improve local blood flow Predrag 2025 Sanja 2025.
Beyond blood vessel growth, BPC-157 activates FAK-paxillin signaling — a cellular machinery that drives cell migration and remodeling of the extracellular matrix (the structural scaffold that holds tissue together) — explaining why wound closure accelerates in animal models Michalina 2025 PubMed 41898733. It also enhances growth hormone receptor expression on tendon fibroblasts (the cells that build connective tissue), which amplifies collagen synthesis even without additional GH input Predrag 2025.
For the gut, BPC-157 takes a distinct path: it upregulates prostaglandins and EGF (epidermal growth factor), strengthens tight junction proteins that seal the intestinal lining, and counteracts NSAID-induced ulceration Michael 2025. Notably, it retains partial stability in gastric acid, which is why oral dosing can work for GI-specific applications — an unusual property for a peptide Predrag 2025.
What the evidence shows
Tendon, muscle, and bone healing Strong rodent evidence; very limited human data
A 2025 systematic review by Vasireddi et al. screened 544 articles and included 36 studies, confirming GH receptor upregulation, angiogenesis pathway activation, and reduced inflammatory cytokines across 35 preclinical studies Nikhil 2025. Rat models consistently show faster healing of surgically detached tendons, torn ligaments, and fractured bone, with one study demonstrating successful quadriceps muscle-to-bone reattachment recovery Danijel 2025. A separate narrative review concluded the preclinical musculoskeletal data is among the most consistent in peptide research P 2025.
Human data remains thin. One retrospective report in the Vasireddi review found that 7 of 12 patients who received intra-articular (directly into the joint) injections reported more than six months of knee pain relief Nikhil 2025. A registered trial for acute hamstring repair is underway NCT07437547, and an earlier pharmacokinetics trial has been completed NCT02637284. Until controlled human trials report, the mechanistic and animal case is compelling, but clinical confirmation is absent.
GI protection and gut barrier repair Strong rodent and in vitro evidence; anecdotal in humans
BPC-157 consistently prevents and reverses NSAID-induced gastric ulcers, colitis-related mucosal damage, and leaky gut (increased intestinal permeability) in animal models, operating through prostaglandin upregulation, EGF signaling, and tight junction restoration Michael 2025 Michalina 2025. Its partial acid stability means the peptide survives the stomach well enough to act locally on the gut lining when taken orally — a property that distinguishes it from most research peptides Predrag 2025.
No controlled human trials have been published specifically for GI indications. Self-reported use in people with IBD and NSAID-related GI damage is common in the community, but that data is anecdotal. The mechanism is clear; the human translation is not yet established.
Anti-inflammatory and pain relief Moderate rodent evidence; very limited human data
BPC-157 downregulates NF-κB (a transcription factor that acts as a master switch for inflammation), reducing downstream pro-inflammatory signals including TNF-α, IL-1β, and IL-6 in multiple animal models Michalina 2025 PubMed 41898733. This anti-inflammatory effect appears to support rather than suppress healing — it reduces chronic, damaging inflammation without fully blunting the acute immune response needed for repair.
The same systematic review that documented musculoskeletal findings noted pain relief as a secondary outcome in the intra-articular human cohort Nikhil 2025, but sample sizes are far too small to draw conclusions. The pain-modulation mechanism via the nitric oxide system is pharmacologically coherent Predrag 2025, but human analgesic evidence remains preliminary.
Neuroprotection and CNS effects Early rodent evidence; no meaningful human data
BPC-157 modulates both iNOS (inducible nitric oxide synthase) and eNOS in neural tissue, showing neuroprotective effects in rodent models of traumatic brain injury, spinal cord damage, and neurotoxin exposure Predrag 2025 PubMed 42021992. Researchers hypothesize the gut-brain axis is one route through which its GI effects translate to CNS outcomes, though this remains speculative. No human neurological trials have been conducted.
How it's used
In studies and self-reported protocols, doses range from 200 mcg to 500 mcg per day. Lower-end dosing (200–250 mcg once daily subcutaneous injection) is common for general use; higher-end protocols (500 mcg once or twice daily) are reported for acute injury. For musculoskeletal injuries, some protocols use localized injections near the injury site rather than systemic subcutaneous injection. Oral dosing (typically capsules or dissolved powder) is used specifically for GI indications, given BPC-157's partial acid stability. The half-life is approximately 4–6 hours via parenteral (injected) routes and shorter orally. No specific food or fasting requirements have been identified. The registered human trial NCT07437547 will provide more structured dosing data when results are available.
Side effects and safety
Across animal studies and self-reported human use, BPC-157 has a notably clean short-term safety profile. Mild nausea, transient injection site redness, dizziness, headache, and fatigue have been reported, but no severe adverse events have been documented in the published literature Nikhil 2025 Michalina 2025. The pharmacokinetics trial NCT02637284 was completed without reported serious adverse events, though full results are not widely published.
The most important theoretical concern is angiogenesis-related: because BPC-157 actively promotes new blood vessel growth via VEGF upregulation, there is a plausible — if unproven — concern about accelerating tumor growth in people with active malignancy or a history of solid tumors. This concern is mechanistic, not documented, but it is taken seriously enough to constitute a contraindication. Long-term safety data in humans simply does not exist. Use during pregnancy or breastfeeding has no safety data. People on anti-VEGF therapies (used in some cancer and eye disease treatments) should be aware of the direct pharmacological conflict.
Bottom line
BPC-157 has one of the most consistent and mechanistically coherent preclinical profiles of any tissue-repair peptide studied to date, with over 100 animal studies and a 2025 systematic review reinforcing its angiogenic, anti-inflammatory, and GI-protective effects Nikhil 2025 Michalina 2025. The gap between animal data and human clinical evidence remains large — one small retrospective cohort and a handful of ongoing trials is the current state of human evidence. It is a reasonable research interest for people managing tendon injuries or GI barrier problems, but anyone with a history of cancer or who is on anti-VEGF therapy should avoid it on mechanistic grounds until more safety data exists.